#	Aladdin ID	Assay Type	Description	Organism	Compounds	Reference	BAO Format	Source
1.	ALA4804300	F	Upregulation of YAP1 protein level in human NCI-H929 cells at 1 to 10 uM measured after 16 hrs by Western blot analysis	Homo sapiens	1	ALA4804281	cell-based format	Patent Bioactivity Data
2.	ALA4804301	F	Upregulation of YAP1 protein level in human MM1.S cells at 1 to 10 uM measured after 16 hrs by Western blot analysis	Homo sapiens	1	ALA4804281	cell-based format	Patent Bioactivity Data
3.	ALA4804305	F	Downregulation of phosphorylated-MOB1 protein level in human MM1.S cells at 1 to 10 uM measured after 6 hrs by Western blot analysis	Homo sapiens	7	ALA4804281	cell-based format	Patent Bioactivity Data
4.	ALA4804306	B	Inhibition of STK4 (unknown origin) using fluorescein-labelled Ser/Thr-07 peptide as substrate incubated for 1 hr in presence of ATP at Km concentration by Z-LYTE assay	Homo sapiens	59	ALA4804281	single protein format	Patent Bioactivity Data
5.	ALA4804307	B	Inhibition of MST4 (unknown origin) using fluorescein-labelled Ser/Thr-07 peptide as substrate incubated for 1 hr in presence of ATP at Km concentration by Z-LYTE assay	Homo sapiens	1	ALA4804281	single protein format	Patent Bioactivity Data
6.	ALA4804308	B	Inhibition of STK3 (unknown origin) using fluorescein-labelled Ser/Thr-07 peptide as substrate incubated for 1 hr in presence of ATP at Km concentration by Z-LYTE assay	Homo sapiens	11	ALA4804281	single protein format	Patent Bioactivity Data
7.	ALA4804309	B	Inhibition of STK24 (unknown origin) using fluorescein-labelled Ser/Thr-07 peptide as substrate incubated for 1 hr in presence of ATP at Km concentration by Z-LYTE assay	Homo sapiens	12	ALA4804281	single protein format	Patent Bioactivity Data
8.	ALA4804310	B	Inhibition of wild-type human full length CSNK1G3 (M1 to K447 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	Homo sapiens	1	ALA4804281	assay format	Patent Bioactivity Data
9.	ALA4804311	B	Inhibition of wild-type human partial length DYRK1A (H129 to S509 residues) expressed in mammalian expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	Homo sapiens	1	ALA4804281	assay format	Patent Bioactivity Data
10.	ALA4804312	B	Inhibition of wild-type human full length GSK3A (M1 to S483 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	Homo sapiens	1	ALA4804281	assay format	Patent Bioactivity Data
11.	ALA4804313	B	Inhibition of wild-type human partial length CIT (M68 to E432 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	Homo sapiens	1	ALA4804281	assay format	Patent Bioactivity Data
12.	ALA4804314	B	Inhibition of wild-type human full length CSNK1E (M1 to K416 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	Homo sapiens	1	ALA4804281	assay format	Patent Bioactivity Data
13.	ALA4804315	B	Inhibition of wild-type human partial length DRAK1 (R32 to E363 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	Homo sapiens	1	ALA4804281	assay format	Patent Bioactivity Data
14.	ALA4804316	B	Inhibition of wild-type human partial length BMPR1B (D178 to L502 residues) expressed in mammalian expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	Homo sapiens	1	ALA4804281	assay format	Patent Bioactivity Data
15.	ALA4804317	B	Inhibition of wild-type human full length DYRK1B (M1 to S629 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	Homo sapiens	1	ALA4804281	assay format	Patent Bioactivity Data
16.	ALA4804318	B	Inhibition of wild-type human partial length MST2 (D17 to E318 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	Homo sapiens	1	ALA4804281	assay format	Patent Bioactivity Data
17.	ALA4804319	B	Inhibition of wild-type human full length CLK1 (M1 to I484 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	Homo sapiens	1	ALA4804281	assay format	Patent Bioactivity Data
18.	ALA4804320	B	Inhibition of wild-type human full length CSNK1A1L (M1 to N337 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	Homo sapiens	1	ALA4804281	assay format	Patent Bioactivity Data
19.	ALA4804321	B	Inhibition of wild-type human partial length VRK2 (M1 to T336 residues) expressed in mammalian expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	Homo sapiens	1	ALA4804281	assay format	Patent Bioactivity Data
20.	ALA4804322	B	Inhibition of wild-type human partial length DCAMKL3 (E140 to V628 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	Homo sapiens	1	ALA4804281	assay format	Patent Bioactivity Data